CORRECTED-Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.46 bln
In this article:
(Corrects Eylea sales in headline and paragraph 1 to $1.46 billion from $1.34 billion)
Jan 8 (Reuters) - Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.46 billion in the United States in the fourth quarter.
Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.
The newer higher dose version of the drug generated about $123 million in sales in the quarter in the United States. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
